EF Hutton Acquisition Co. I Upgrades NRx Pharmaceuticals (NASDAQ:NRXP) to Strong-Buy

NRx Pharmaceuticals (NASDAQ:NRXP) was upgraded by investment analysts at EF Hutton Acquisition Co. I to a “strong-buy” rating in a research report issued on Monday, Zacks.com reports.

NRXP has been the subject of a number of other reports. HC Wainwright lifted their price target on shares of NRx Pharmaceuticals from $2.00 to $19.00 and gave the company a “buy” rating in a research report on Monday, August 5th. Ascendiant Capital Markets lifted their price target on shares of NRx Pharmaceuticals from $43.00 to $44.00 and gave the company a “buy” rating in a research report on Thursday, September 12th.

NRx Pharmaceuticals Stock Down 3.2 %

NASDAQ:NRXP opened at $1.20 on Monday. The stock has a market capitalization of $12.84 million, a price-to-earnings ratio of -0.38 and a beta of 1.25. NRx Pharmaceuticals has a 52 week low of $1.10 and a 52 week high of $7.33. The stock’s fifty day moving average is $1.65 and its two-hundred day moving average is $2.57.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.06. On average, sell-side analysts expect that NRx Pharmaceuticals will post -3.25 EPS for the current fiscal year.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.